Sangamo Biosciences (SGMO) just unveiled an update.
At Sangamo Therapeutics’ Annual Meeting on June 4, 2024, stockholders approved several key proposals, including the expansion of the 2018 Equity Incentive Plan by 11 million shares and increasing the total authorized common stock to 960 million shares. Additionally, they elected nine directors to the board, endorsed executive compensation, and ratified Ernst & Young LLP as their independent accounting firm for the upcoming fiscal year. These strategic moves are designed to incentivize performance and prepare the company for future growth.
See more insights into SGMO stock on TipRanks’ Stock Analysis page.
